Company intelligence / Profile preview

PWR Lift

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

LIfT BioSciences is advancing its IMAN (Immuno-Modulatory Alpha Neutrophils) cell therapy to Phase I clinical trials with first patient dosing expected in Q4 2026[2][4]. The therapy has demonstrated superiority over pembrolizumab (Keytruda) in preclinical organ-on-a-chip models[2]. The company secured a €12 million grant from Ireland's Disruptive Technologies Innovation Fund in July 2025, the largest grant awarded by DTIF to date[4].

Therapeutic areas: Oncology
Modalities: Cell therapyAllogeneic cell therapy
Industry: Biotech

Partnerships

University of Galway (consortium partner for DTIF grant, expertise in cell therapy development and clinical trials)[4]Hooke Bio (consortium partner, immuno-analytics platform)[4]Multiple unnamed pharma companies interested in providing free drugs for combination trials[2]

Beyond the preview

Go deeper on PWR Lift.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PWR Lift.

Explore the full profile